The Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Based on FOLFIRI for Advanced Intrahepatic Cholangiocarcinoma as Second-Line and Successive Treatment: A Real-World Study
Open Access
- 26 September 2022
- journal article
- research article
- Published by Wiley in Canadian Journal of Gastroenterology and Hepatology
- Vol. 2022, 1-7
Abstract
Objective. Intrahepatic cholangiocarcinoma (iCCA) is a primary liver malignancy with a poor prognosis and limited treatment. Cisplatin with gemcitabine is used as the standard first-line chemotherapy regimen; however, there is still no robust evidence for second-line and successive treatments. Although preliminary evidence suggests a vital role of precision therapy or immunotherapy in a subset of patients, the gene alteration rate is relatively low. Herein, we explored the second-line and successive treatments using hepatic arterial infusion chemotherapy (HAIC) based on FOLFIRI after the failure of gemcitabine and platinum combined with target and immunotherapy in refractory CCAs. Methods. Advanced patients with iCCAs confirmed by diagnostic pathology, who progressed at least on a gemcitabine/platinum doublet and/or other systemic chemotherapy combined with target therapy and immune checkpoint inhibitor, were included. All patients received infusional 5-fluorouracil/leucovorin with irinotecan (FOLFIRI) via HAIC until progression or unacceptable toxicity. The primary objective was the feasibility of treatment, with secondary objectives of disease control rate (DCR) and 6-month survival rate. Results. A total of 9 iCCA patients treated between Dec 2020 and May 2021 were enrolled; 2 patients suffered from distant metastasis, while 7 had local lymph node metastasis and portal vein or hepatic vein invasion. HAIC was delivered as second-line therapy in 6/9 patients, while a third or successive therapy in 3/9 patients. The patients accepted an average of 2.90±1.69 cycles of HAIC. The objective response rate was 22.2; the disease control rate was 55.5 (5/9); median progression-free survival was 5months; and 6-month survival rate was 66.7 (6/9). Conclusions. Our results provide preliminary evidence that HAIC based on FOLFIRI regimen is efficient and safe in some patients progressing after previous treatment. Therefore, HAIC may be a promising and valuable complementary therapy for advanced CCAs as a second-line and successive therapy. Otherwise, the combination of HAIC with precision medicine may improve clinical benefits (clinical registration number: 2021BAT4857).Keywords
Funding Information
- National Natural Science Foundation of China (81972232, 82072575, 18410720700, 20JC1419103, 21ZR1412200, 2019YFC1316000)
- Natural Science Foundation of Shanghai Municipality (81972232, 82072575, 18410720700, 20JC1419103, 21ZR1412200, 2019YFC1316000)
- National Basic Research Program of China (81972232, 82072575, 18410720700, 20JC1419103, 21ZR1412200, 2019YFC1316000)
This publication has 31 references indexed in Scilit:
- Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trialEuropean Journal of Cancer, 2017
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockadeScience, 2017
- A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinomaCancer, 2017
- New molecular and immunotherapeutic approaches in biliary cancerESMO Open, 2017
- Mismatch Repair Deficiency and Response to Immune Checkpoint BlockadeThe Oncologist, 2016
- Prognostic factors for progression-free and overall survival in advanced biliary tract cancerAnnals of Oncology, 2015
- Genomic spectra of biliary tract cancerNature Genetics, 2015
- Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: A systematic review and pooled analysisEuropean Journal of Surgical Oncology, 2015
- Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in JapanBritish Journal of Cancer, 2010
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract CancerNew England Journal of Medicine, 2010